Skip to Content
Merck
All Photos(3)

Key Documents

View All Documentation

D122

Sigma-Aldrich

Domperidone

powder, ≥98% (HPLC)

Synonym(s):

4-(5-Chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

Empirical Formula (Hill Notation):
C22H24ClN5O2
CAS Number:
57808-66-9
Molecular Weight:
425.91
EC Number:
260-968-7
MDL number:
MFCD00069256
UNSPSC Code:
12352200
PubChem Substance ID:
24277911
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

color

white

solubility

DMSO: >10 mg/mL
0.1 M HCl: soluble
0.1 M NaOH: slightly soluble
H2O: insoluble

originator

Johnson & Johnson

SMILES string

Clc1ccc2N(C3CCN(CCCN4C(=O)Nc5ccccc45)CC3)C(=O)Nc2c1

InChI

1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)

InChI key

FGXWKSZFVQUSTL-UHFFFAOYSA-N

Gene Information

human ... DRD1(1812) , DRD2(1813) , DRD3(1814) , DRD4(1815) , DRD5(1816) , KCNH2(3757)
rat ... Drd1a(24316) , Drd2(24318) , Drd3(29238) , Htr3a(79246)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Peripheral dopamine receptor antagonist that does not cross the blood-brain barrier; anti-emetic.

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361fd

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity.
P M Laduron et al.
Biochemical pharmacology, 28(14), 2161-2165 (1979-07-15)
D S Pritchard et al.
British journal of clinical pharmacology, 59(6), 725-729 (2005-06-14)
To determine whether there is robust evidence of efficacy for domperidone in reducing the symptoms of gastro-oesophageal reflux (GOR) and gastro-oesophageal reflux disease (GORD) in children. Systematic review of randomized controlled trials (RCTs). A search was made of the Cochrane
Luc M Hondeghem
Journal of cardiovascular pharmacology, 61(3), 218-225 (2012-11-29)
Domperidone (antinausea/vomiting agent) was recently shown by several groups to increase sudden cardiac death (SCD). Drug-induced disturbances of cardiac repolarization may be a major mechanism. Experiments were executed in isolated female rabbit hearts perfused for 150 minutes with domperidone 30
M C Champion et al.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 135(5), 457-461 (1986-09-01)
Domperidone is a dopamine antagonist that has recently been released in Canada. Unlike metoclopramide hydrochloride, the other available dopamine antagonist, it does not readily enter the central nervous system. Domperidone acts as both an antiemetic and an upper gastrointestinal tract
R N Brogden et al.
Drugs, 24(5), 360-400 (1982-11-01)
Domperidone is a dopamine antagonist that does not readily enter the central nervous system. Given parenterally or orally it increases gastric emptying of liquids and increases lower oesophageal sphincter pressure in healthy subjects. The antiemetic and pharmacodynamic profile of domperidone
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service